Cell Biology Quiz: Gene Therapy And Crispr
20 questions · exam conditions
0:00
Gene Therapy And CrisprQuestion 1 of 20

A research team is developing a CRISPR-Cas9 gene therapy to treat a patient with a single nucleotide deletion in the CFTR gene. The deletion occurs in exon 11 and causes a frameshift mutation. Which of the following approaches would be most appropriate for correcting this defect?

Use a guide RNA that targets the deletion site and rely on non-homologous end joining (NHEJ) to repair the gap
Design a guide RNA that cuts upstream of the deletion and provide a donor template containing the missing nucleotide for homology-directed repair (HDR)
Target multiple sites throughout the CFTR gene simultaneously to increase the probability of successful repair
Use base editing to convert an adjacent cytosine to thymine, which will compensate for the reading frame shift
Employ prime editing to directly insert the missing nucleotide without creating double-strand breaks
← Back to quizzes

Cell Biology Quiz

Cell Biology Quiz: Gene Therapy And Crispr

Practice Gene Therapy And Crispr in Cell Biology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Gene Therapy And Crispr, giving you a quick way to practice the rules, question types, and explanations that matter most for Cell Biology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A research team is developing a CRISPR-Cas9 gene therapy to treat a patient with a single nucleotide deletion in the CFTR gene. The deletion occurs in exon 11 and causes a frameshift mutation. Which of the following approaches would be most appropriate for correcting this defect?

  1. Use a guide RNA that targets the deletion site and rely on non-homologous end joining (NHEJ) to repair the gap
  2. Design a guide RNA that cuts upstream of the deletion and provide a donor template containing the missing nucleotide for homology-directed repair (HDR) (correct answer)
  3. Target multiple sites throughout the CFTR gene simultaneously to increase the probability of successful repair
  4. Use base editing to convert an adjacent cytosine to thymine, which will compensate for the reading frame shift
  5. Employ prime editing to directly insert the missing nucleotide without creating double-strand breaks
Explanation: When you encounter CRISPR-Cas9 gene therapy questions, focus on matching the repair mechanism to the type of genetic defect. A single nucleotide deletion causing a frameshift mutation requires precise insertion of the missing nucleotide to restore the correct reading frame. Option B is correct because homology-directed repair (HDR) is the only mechanism that can precisely insert specific DNA sequences. By designing a guide RNA to cut upstream of the deletion and providing a donor template containing the missing nucleotide, the cell's HDR machinery can use the template to accurately repair the gap, restoring the proper reading frame and CFTR function. Option A fails because non-homologous end joining (NHEJ) is an imprecise repair mechanism that randomly inserts or deletes nucleotides at double-strand breaks. This would likely worsen the frameshift rather than correct it, as NHEJ cannot specifically insert the one missing nucleotide needed. Option C is problematic because targeting multiple sites simultaneously would create numerous double-strand breaks throughout the gene, leading to extensive chromosomal damage and likely destroying CFTR function entirely rather than repairing the single deletion. Option D won't work because base editing changes one nucleotide to another but cannot insert missing nucleotides. Converting a cytosine to thymine at an adjacent site would create an additional mutation without addressing the original deletion or correcting the frameshift. Study tip: Remember that frameshift mutations from insertions or deletions require HDR with a donor template for precise correction, while point mutations can often be fixed with base editing or sometimes NHEJ.

Question 2

A gene therapy clinical trial uses an adeno-associated virus (AAV) vector to deliver a therapeutic gene to hepatocytes. After the first round of treatment, many patients develop neutralizing antibodies against the AAV capsid proteins. What is the most significant consequence of this immune response for future treatments?

  1. The therapeutic gene will be silenced by RNA interference mechanisms activated by the antibodies
  2. Subsequent AAV vectors will be rapidly cleared before they can transduce target cells effectively (correct answer)
  3. The patients will develop autoimmune reactions against their own hepatocytes expressing the therapeutic gene
  4. The AAV vectors will integrate randomly into the host genome, increasing the risk of insertional mutagenesis
  5. The Cas9 protein will be degraded by antibody-dependent cellular cytotoxicity before reaching the nucleus
Explanation: When you encounter gene therapy questions involving viral vectors, focus on the immune system's response to foreign proteins and how this affects therapeutic efficacy over time. AAV vectors are coated with capsid proteins that the immune system recognizes as foreign. After initial exposure, patients develop neutralizing antibodies specifically targeting these capsid proteins. When subsequent AAV treatments are administered, these pre-existing antibodies immediately bind to the viral capsids, marking them for destruction by the immune system. This rapid clearance prevents the vectors from reaching hepatocytes and delivering their therapeutic cargo, making B correct. A is wrong because antibodies don't directly activate RNA interference mechanisms. RNAi involves small RNA molecules that bind to complementary mRNA sequences, which is unrelated to antibody-mediated immune responses. C misrepresents the immune target. The neutralizing antibodies are directed against viral capsid proteins, not the therapeutic gene product or hepatocytes themselves. While autoimmunity is theoretically possible in gene therapy, it's not the primary concern with AAV capsid antibodies. D describes a risk associated with integrating vectors like retroviruses, but AAV vectors typically remain episomal (don't integrate into the host genome). Additionally, antibodies wouldn't influence integration patterns even if integration occurred. Study tip: For viral vector questions, remember the sequence: first exposure → immune recognition → antibody production → reduced efficacy on re-exposure. This pattern applies to most viral gene therapy vectors and explains why researchers are developing capsid variants to evade pre-existing immunity.

Question 3

A pharmaceutical company is developing a gene therapy for beta-thalassemia using a lentiviral vector to deliver a functional beta-globin gene. During preclinical testing, they discover that the therapeutic gene is being silenced over time in some patients' cells. Which modification to their vector design would most effectively address this issue?

  1. Replace the lentiviral vector with an adenoviral vector to avoid integration-associated silencing
  2. Include chromatin insulator sequences flanking the therapeutic gene cassette in the vector (correct answer)
  3. Increase the copy number of the therapeutic gene within each vector particle
  4. Add a nuclear localization signal to the beta-globin protein to enhance its cellular uptake
  5. Use a tissue-specific promoter instead of a ubiquitous promoter to drive gene expression
Explanation: When you encounter gene therapy questions involving vector silencing, focus on the mechanisms that cause therapeutic genes to lose expression over time and the strategies to prevent this. Gene silencing in viral vectors often occurs due to chromatin remodeling and epigenetic modifications that shut down transgene expression. The host cell's machinery can recognize foreign DNA sequences and gradually silence them through heterochromatin formation and DNA methylation. This is particularly problematic with integrating vectors like lentiviruses, where the therapeutic gene becomes permanently incorporated into the host genome but may still be silenced by surrounding chromatin. Chromatin insulator sequences (answer B) are the most effective solution because they create boundaries that protect the therapeutic gene from silencing effects. These sequences prevent the spread of heterochromatin and maintain an open, transcriptionally active chromatin structure around the gene cassette, ensuring sustained expression over time. Answer A is incorrect because switching to adenoviral vectors would actually worsen the problem—adenoviruses don't integrate into the genome, so the therapeutic effect would be temporary as the vectors are cleared. Answer C misses the point entirely; increasing gene copy number won't prevent silencing and may actually trigger stronger silencing responses. Answer D shows a fundamental misunderstanding—beta-globin is a cytoplasmic protein that doesn't need nuclear localization, and this modification wouldn't address the transcriptional silencing issue. Remember: for gene therapy silencing problems, look for epigenetic solutions like insulators or modified promoters rather than changing vector types or protein modifications.

Question 4

Scientists are using base editing to correct a C→T point mutation that causes a premature stop codon in the dystrophin gene. They employ a cytosine base editor (CBE) but find that it creates unwanted C→T conversions at nearby cytosines within the editing window. What strategy would most effectively reduce these off-target edits while maintaining on-target correction?

  1. Increase the concentration of the base editor components to saturate all available cytosines
  2. Use a shorter guide RNA to reduce the size of the editing window around the target site
  3. Switch to an adenine base editor (ABE) and target the opposite DNA strand
  4. Engineer the cytosine deaminase domain to have narrower sequence specificity preferences (correct answer)
  5. Co-deliver a DNA repair inhibitor to prevent cellular correction of the intended base changes
Explanation: When you encounter base editing questions, focus on the core challenge: achieving precision while minimizing off-target effects. Base editors work within an "editing window" where the deaminase enzyme can access and modify bases, but this creates a fundamental specificity problem. The most effective solution is engineering the cytosine deaminase domain to have narrower sequence specificity preferences (D). By modifying the enzyme's active site or binding domains, you can make it more selective for the specific sequence context around your target cytosine. This directly addresses the root cause—the enzyme's promiscuous activity—while maintaining its ability to edit the desired site. Option A is counterproductive because increasing editor concentration would actually worsen off-target effects by saturating more cytosines, not fewer. Higher concentrations typically increase both on-target and off-target activity proportionally. Option B won't work because you can't simply shorten the guide RNA to shrink the editing window. The editing window size is determined by the physical structure of the base editor complex and the deaminase domain's reach, not the guide RNA length. Option C misses the point entirely. Switching to an adenine base editor and targeting the opposite strand wouldn't correct a C→T mutation—you'd need to convert an A→G on the complementary strand, which creates unnecessary complexity and doesn't address the specificity problem. Remember: base editing precision problems are best solved at the enzyme level through protein engineering, not by adjusting targeting components or concentrations.

Question 5

A research team is developing an in vivo CRISPR gene therapy for Leber congenital amaurosis caused by mutations in the CEP290 gene. They plan to inject the CRISPR components directly into the subretinal space. What is the primary advantage of this local delivery approach compared to systemic administration?

  1. Local injection completely eliminates the risk of off-target effects in non-retinal tissues
  2. The blood-retinal barrier enhances CRISPR component stability and prevents degradation
  3. Higher concentrations can be achieved in target photoreceptor cells while minimizing systemic exposure (correct answer)
  4. Retinal cells have enhanced DNA repair mechanisms that improve gene editing efficiency
  5. The immune-privileged status of the eye prevents any inflammatory responses to the CRISPR components
Explanation: When evaluating drug delivery strategies, you need to consider the relationship between local versus systemic administration and how anatomical barriers affect therapeutic targeting. This is especially critical for gene therapies like CRISPR, where precise delivery to specific tissues is essential. Subretinal injection allows CRISPR components to be delivered directly to the target tissue—photoreceptor cells in the retina—achieving much higher local concentrations than would be possible with systemic delivery. This targeted approach also minimizes exposure to other organs and tissues throughout the body, reducing the likelihood of unintended effects in non-target cells. The eye's relatively isolated anatomy makes it an ideal candidate for local delivery strategies. Looking at the incorrect options: Choice A overstates the benefits—local delivery reduces but doesn't completely eliminate off-target risks, as CRISPR can still have off-target effects within the treated tissue itself. Choice B mischaracterizes the blood-retinal barrier's role; while this barrier does limit systemic drug penetration into the eye (which is why local delivery is preferred), it doesn't specifically enhance CRISPR stability or prevent degradation. Choice D incorrectly suggests that retinal cells have superior DNA repair mechanisms—there's no evidence that photoreceptor cells have enhanced repair systems compared to other cell types. Remember that local delivery questions often test your understanding of pharmacokinetic principles: higher local concentrations with reduced systemic exposure is typically the primary advantage of direct tissue injection, especially in immunologically privileged sites like the eye.

Question 6

A gene therapy trial for X-linked severe combined immunodeficiency (X-SCID) uses a retroviral vector to deliver a functional IL2RG gene to patient T-cells ex vivo before reinfusion. Several patients develop leukemia years after treatment. Investigation reveals that the therapeutic vector integrated near the LMO2 oncogene in the leukemic cells. What mechanism most likely contributed to the development of leukemia?

  1. The IL2RG therapeutic gene product directly activated oncogenic signaling pathways in T-cells
  2. Retroviral enhancer sequences in the vector activated inappropriate expression of the nearby LMO2 gene (correct answer)
  3. The integration process caused a chromosomal translocation that fused IL2RG with LMO2
  4. Vector-encoded viral proteins persisted in the cells and transformed them through oncogenic mechanisms
  5. The ex vivo culture conditions used for gene therapy induced mutagenic stress in the treated cells
Explanation: When you encounter gene therapy questions involving retroviral vectors and cancer development, focus on how viral regulatory sequences can affect nearby genes after integration. Retroviruses contain powerful regulatory elements called long terminal repeats (LTRs) that include enhancer and promoter sequences. These elements are designed to drive strong expression of viral genes, but when the virus integrates into the host genome, these same regulatory sequences can inappropriately activate nearby cellular genes. In this case, the retroviral vector integrated near LMO2, a known oncogene involved in T-cell development. The viral enhancer sequences likely caused overexpression of LMO2, leading to uncontrolled cell growth and leukemia. This phenomenon, called insertional mutagenesis, was a significant problem in early gene therapy trials. Choice A is incorrect because IL2RG (which encodes the common gamma chain receptor) normally functions in immune signaling, not oncogenic transformation. Choice C describes a chromosomal translocation creating a fusion protein, but the question indicates the vector integrated "near" LMO2, not within it, and there's no evidence of fusion protein formation. Choice D suggests persistent viral proteins caused transformation, but therapeutic retroviral vectors are typically designed to be replication-defective and don't produce transforming viral proteins. For gene therapy questions, remember that the location of vector integration matters enormously. Vectors integrating near oncogenes or tumor suppressors can disrupt normal gene regulation through their regulatory sequences, even when the therapeutic gene itself is completely normal.

Question 7

A research team is developing a dual-vector approach for large gene delivery, splitting a therapeutic gene across two AAV vectors that must recombine in target cells. They include overlapping sequences to facilitate recombination. In their studies, they observe that recombination efficiency is much higher in dividing cells compared to post-mitotic neurons. What cellular process most likely accounts for this difference?

  1. Dividing cells express higher levels of Cas9 protein needed for vector recombination
  2. The nuclear envelope breakdown during mitosis allows better mixing of vector components
  3. Homologous recombination machinery is more active during S-phase of the cell cycle (correct answer)
  4. Post-mitotic cells have more condensed chromatin that prevents vector DNA accessibility
  5. Dividing cells have larger cytoplasmic volumes that accommodate both vector particles more effectively
Explanation: When you encounter questions about gene delivery and recombination efficiency, focus on how different cellular states affect DNA repair and recombination processes. This question tests your understanding of cell cycle-dependent molecular machinery. The key insight is that homologous recombination machinery is most active during S-phase when cells are naturally replicating their DNA. During S-phase, cells upregulate DNA repair proteins like RAD51, BRCA1, and BRCA2, which are essential for homologous recombination between the overlapping sequences of the two AAV vectors. Dividing cells also have active DNA polymerases and other replication machinery that can facilitate the recombination process. In contrast, post-mitotic neurons have minimal expression of these proteins since they're not actively replicating DNA, making recombination between vectors much less efficient. Looking at the wrong answers: (A) is incorrect because Cas9 is not involved in AAV vector recombination—it's a CRISPR-associated protein for targeted cutting, not natural cellular recombination. (B) misunderstands the process; nuclear envelope breakdown during mitosis wouldn't improve recombination since the vectors need to integrate into DNA, which requires the cell cycle machinery active during S-phase, not the physical mixing during mitosis. (D) is partially true that post-mitotic cells have condensed chromatin, but this isn't the primary limiting factor—the lack of active recombination machinery is more significant. Remember: when comparing dividing versus non-dividing cells for DNA processes, always consider which cell cycle phase provides the necessary molecular machinery for the specific process described.

Question 8

Researchers are developing a CRISPR-based epigenome editing approach to treat Fragile X syndrome by removing methyl groups from the silenced FMR1 gene promoter. They use dCas9 fused to a demethylase enzyme and target it to CpG sites in the promoter region. Initial results show successful demethylation, but FMR1 expression remains low. What additional epigenetic modification would most likely need to be addressed?

  1. Histone H3 lysine 27 trimethylation (H3K27me3) marks associated with Polycomb-mediated silencing (correct answer)
  2. Histone H3 lysine 4 trimethylation (H3K4me3) marks that prevent transcriptional initiation
  3. DNA hydroxymethylation at cytosine residues that maintains transcriptional repression
  4. Histone H2A ubiquitination that blocks RNA polymerase II elongation through the gene body
  5. Chromatin loop formation that sequesters the FMR1 promoter away from transcriptional machinery
Explanation: When approaching epigenome editing questions, think about the layered nature of epigenetic silencing. Gene silencing typically involves multiple reinforcing mechanisms that work together, so addressing just one layer may not fully restore expression. In Fragile X syndrome, the FMR1 gene promoter becomes hypermethylated and transcriptionally silenced. While the researchers successfully removed DNA methylation, they're dealing with a classic example of how epigenetic silencing mechanisms reinforce each other. DNA methylation often recruits additional silencing complexes that establish their own repressive marks. The correct answer is A. Polycomb Repressive Complex 2 (PRC2) is frequently recruited to methylated CpG islands and deposits H3K27me3 marks, creating a stable silencing complex. Even after DNA demethylation, these histone modifications can maintain transcriptional repression independently. The researchers would need to target both the DNA methylation and the H3K27me3 marks to fully reactivate FMR1 expression. Answer B is incorrect because H3K4me3 is actually an activating mark associated with active promoters, not a silencing mechanism. Answer C misunderstands hydroxymethylation - this modification is generally associated with active demethylation and gene activation, not repression. Answer D incorrectly suggests H2A ubiquitination blocks elongation, but the primary issue here is transcriptional initiation at the promoter level, not elongation through the gene body. Remember that epigenetic silencing often involves multiple layers. When one mechanism is removed but expression doesn't recover, look for additional repressive marks that need to be addressed.

Question 9

A pharmaceutical company is testing an mRNA-based gene therapy for alpha-1 antitrypsin deficiency. The therapeutic mRNA is delivered in lipid nanoparticles and shows good protein expression initially, but levels decline rapidly over time. Which modification to the mRNA design would most effectively extend the duration of protein expression?

  1. Increase the number of adenine residues in the 3' poly(A) tail to enhance mRNA stability
  2. Replace natural uridine residues with pseudouridine to reduce innate immune recognition
  3. Add multiple internal ribosome entry sites (IRES) to increase translation efficiency
  4. Include nuclear localization signals in the coding sequence to protect mRNA from cytoplasmic degradation
  5. Design the mRNA to encode a self-amplifying replicon system that maintains expression over time (correct answer)
Explanation: When evaluating mRNA therapeutics with declining protein expression, you need to consider the primary factors that limit mRNA persistence and function in cells: stability, immune recognition, translation efficiency, and cellular localization. The most effective approach is A) increasing adenine residues in the 3' poly(A) tail. The poly(A) tail is crucial for mRNA stability and translation. Longer poly(A) tails protect mRNA from 3' to 5' exonuclease degradation and enhance ribosome binding, directly addressing the rapid decline in protein expression. This modification extends mRNA half-life significantly without introducing foreign sequences. B) Replacing uridine with pseudouridine helps reduce immune activation through Toll-like receptors, which is important for avoiding inflammatory responses, but this primarily affects initial expression rather than duration. If the mRNA is already expressing well initially, immune recognition isn't the limiting factor. C) Adding multiple IRES sequences could actually be counterproductive. IRES elements are large, complex structures that can destabilize mRNA and create unpredictable translation patterns. Since translation efficiency seems adequate (good initial expression), this adds unnecessary complexity. D) Nuclear localization signals represent a fundamental misunderstanding—mRNA functions in the cytoplasm where ribosomes are located. Directing mRNA to the nucleus would prevent translation entirely and offer no protection advantage. Study tip: For mRNA therapeutic questions, remember the hierarchy: stability first (poly(A) tail, 5' cap), then immune evasion, then translation optimization. Address the most fundamental limitation causing the observed problem.

Question 10

Researchers are testing a prime editing approach to correct the most common CFTR mutation (F508del) in cystic fibrosis patient cells. They design a pegRNA to restore the deleted phenylalanine codon but observe that even successfully edited cells still show reduced CFTR function compared to wild-type controls. What cellular factor most likely contributes to this persistent functional deficit?

  1. The prime editing process introduces secondary mutations that disrupt other regions of the CFTR protein
  2. Chronic endoplasmic reticulum stress in patient cells has permanently damaged the protein folding machinery
  3. The restored CFTR protein retains conformational instability that affects its trafficking and function (correct answer)
  4. Prime editing efficiency is incomplete, leaving a mixed population of corrected and uncorrected cells
  5. Patient cells have developed compensatory changes that interfere with normal CFTR channel activity
Explanation: When you encounter questions about gene editing outcomes, especially involving protein misfolding diseases, consider both the immediate genetic correction and the underlying protein biology that caused the original disease. The F508del mutation in CFTR doesn't just remove a phenylalanine residue—it fundamentally destabilizes the protein's structure. Even when prime editing successfully restores the missing codon, the CFTR protein often retains conformational problems that impair its folding, trafficking from the endoplasmic reticulum to the cell surface, and ultimate function as a chloride channel. This is because the F508 residue plays a critical role in stabilizing interactions between different domains of the CFTR protein. Without perfect restoration of these structural relationships, the corrected protein may still be recognized as misfolded by cellular quality control systems. Option A is incorrect because prime editing is highly precise and rarely introduces off-target mutations, especially not consistently across all edited cells. Option B misrepresents how ER stress works—while chronic stress can impair cellular function, the protein folding machinery isn't "permanently damaged" and would affect all proteins, not just CFTR. Option D doesn't explain why even the successfully corrected cells show reduced function compared to wild-type controls. Remember that genetic correction doesn't always equal functional correction, especially with structural proteins. When studying protein misfolding diseases, focus on understanding how mutations affect protein structure and stability, not just sequence. This principle applies broadly to conditions like sickle cell disease, Huntington's disease, and many others where the relationship between genotype and phenotype involves complex protein biology.

Question 11

A biotechnology company is developing a gene therapy for hemophilia A using a novel AAV variant with enhanced liver tropism. During dose-escalation studies, they find that higher vector doses lead to diminishing returns in Factor VIII expression rather than proportional increases. What mechanism most likely accounts for this saturation effect?

  1. High vector concentrations trigger innate immune responses that reduce hepatocyte transduction efficiency
  2. Competition between vector particles for cellular uptake receptors limits the number that can enter each cell
  3. Increased vector doses overwhelm the cellular transcription machinery available for Factor VIII gene expression
  4. Vector DNA integration sites become saturated, preventing additional copies from inserting into the genome
  5. Factor VIII protein expression is limited by the cellular capacity for proper protein folding and secretion (correct answer)
Explanation: When analyzing gene therapy dose responses, you need to consider the cellular machinery involved in vector processing and gene expression. AAV vectors must navigate multiple steps: cellular entry, trafficking to the nucleus, DNA release, and transcriptional activation. The saturation effect at higher doses occurs because AAV vectors exist as episomes (non-integrated circular DNA) in the nucleus, and there's limited nuclear space and chromatin accessibility for these episomal genomes to establish productive transcription units. As vector doses increase, the nuclear environment becomes crowded with competing episomal DNA molecules, and the cellular transcription machinery becomes overwhelmed trying to process multiple copies of the therapeutic gene. Answer A incorrectly focuses on immune responses affecting transduction, but the question describes successful transduction with diminishing expression returns, not reduced cellular uptake. Answer B suggests receptor saturation limits cellular entry, but this would affect transduction efficiency rather than expression per transduced cell. Answer C mentions transcriptional machinery saturation, which is partially correct but doesn't capture the full mechanism of episomal DNA competition and nuclear organization constraints. Answer D incorrectly assumes AAV integration - AAV vectors typically remain episomal and don't integrate into the host genome. For gene therapy questions, remember that AAV biology differs from integrating vectors like lentiviruses. AAV forms episomes that compete for nuclear real estate and transcriptional resources. This creates an upper limit on expression that's independent of the number of vector particles delivered, explaining why dose escalation often shows diminishing returns in clinical applications.

Question 12

Researchers are using CRISPR-Cas9 to create a cellular model of Huntington's disease by introducing CAG repeat expansions into the huntingtin gene of healthy neurons. They observe that some cells show the expected phenotype while others remain normal despite successful Cas9 cutting. What is the most likely explanation for this variability?

  1. The guide RNA has off-target effects that interfere with huntingtin gene expression in some cells
  2. Non-homologous end joining repair creates different outcomes at the cut site in different cells (correct answer)
  3. Some cells express higher levels of DNA repair enzymes that prevent CAG repeat expansion
  4. The Cas9 protein degrades rapidly in certain cell types, preventing complete gene editing
  5. Chromatin accessibility varies between cells, affecting guide RNA binding efficiency at the target site
Explanation: When CRISPR-Cas9 cuts DNA, cells must repair the break through one of several pathways, and this repair process is inherently variable and unpredictable. Understanding DNA repair mechanisms is crucial for interpreting CRISPR outcomes. The most likely explanation is B) Non-homologous end joining repair creates different outcomes at the cut site in different cells. When Cas9 cuts the huntingtin gene, cells primarily use non-homologous end joining (NHEJ) to repair the break. NHEJ is an error-prone process that randomly inserts or deletes nucleotides at the cut site. In some cells, these random insertions might include CAG repeats (creating the desired disease model), while in others, the repair might not generate the pathogenic expansion or could even disrupt the gene differently. This inherent randomness of NHEJ perfectly explains why identical cutting events lead to different phenotypic outcomes. A is incorrect because off-target effects would affect huntingtin expression elsewhere, not create variability specifically at the intended cut site. C misunderstands the process—higher DNA repair enzyme levels wouldn't prevent CAG expansion but would simply repair the break more efficiently through the same random NHEJ process. D is wrong because if Cas9 degraded before cutting, those cells wouldn't show any editing at all, yet the question states that cutting was successful in all cells. Remember that CRISPR success isn't just about cutting—the cellular repair response determines the final outcome. NHEJ's inherent randomness means that even perfect cutting can yield variable results, making it essential to screen multiple edited clones.

Question 13

Scientists are using CRISPR-Cas9 to perform multiplexed gene editing, simultaneously targeting five different genes involved in cholesterol metabolism. They notice that editing efficiency decreases as they add more guide RNAs to the system. Which factor most likely limits the effectiveness of this multiplexed approach?

  1. Competition between guide RNAs for binding to the limited pool of Cas9 protein in each cell
  2. Increased cellular stress responses triggered by multiple simultaneous double-strand breaks (correct answer)
  3. Reduced specificity of individual guide RNAs due to increased off-target binding opportunities
  4. Saturation of the nuclear import machinery preventing efficient delivery of all guide RNA-Cas9 complexes
  5. Interference between DNA repair processes occurring simultaneously at multiple genomic loci
Explanation: When you encounter CRISPR multiplexing questions, focus on what happens when cells experience multiple simultaneous DNA breaks and the cellular response mechanisms that kick in. The correct answer is B because cells have sophisticated damage detection systems that respond to double-strand breaks (DSBs). When CRISPR-Cas9 cuts DNA at multiple sites simultaneously, it triggers cellular stress responses including DNA damage checkpoints, cell cycle arrest, and potentially apoptosis pathways. These stress responses divert cellular resources away from the editing process and can lead to cell death, dramatically reducing overall editing efficiency. The more simultaneous cuts you make, the stronger this stress response becomes. Option A is incorrect because Cas9 protein availability isn't typically the limiting factor - researchers can adjust protein concentrations, and cells can accommodate multiple guide RNA-Cas9 complexes. Option C misunderstands specificity - adding more guide RNAs doesn't inherently make individual guides less specific, as each guide RNA maintains its unique target sequence recognition. Option D incorrectly focuses on nuclear import, which generally isn't saturated under normal experimental conditions and can handle the molecular traffic from multiple guide RNA complexes. The key insight is that cells treat multiple simultaneous DNA breaks as a crisis requiring emergency response, not routine repair. This biological safety mechanism evolved to protect genome integrity but becomes a limitation in multiplexed editing applications. Study tip: For CRISPR questions, always consider the cell's perspective - multiple DNA breaks simultaneously trigger stress responses that can override the intended editing outcomes.

Question 14

A clinical trial for Duchenne muscular dystrophy uses antisense oligonucleotides to restore the dystrophin reading frame by skipping exon 51. While the treatment successfully increases dystrophin protein levels, the clinical benefit is modest. Muscle biopsies reveal that dystrophin is present but shows altered subcellular localization. What is the most likely explanation for this finding?

  1. The antisense oligonucleotides are interfering with dystrophin mRNA translation at the ribosome
  2. Exon 51 skipping creates an in-frame deletion that removes critical protein domains needed for proper localization (correct answer)
  3. Compensatory muscle fiber regeneration dilutes the dystrophin signal throughout the tissue
  4. The restored dystrophin lacks post-translational modifications required for membrane association
  5. Inflammatory processes in dystrophic muscle prevent proper assembly of the dystrophin-glycoprotein complex
Explanation: When you encounter questions about therapeutic approaches for genetic diseases, focus on how molecular interventions affect protein structure and function. Exon skipping therapy aims to restore the reading frame by removing problematic exons, but this creates an internally deleted protein. Exon 51 skipping successfully restores dystrophin production by eliminating a frameshift mutation, but the resulting protein lacks the amino acid sequences encoded by exon 51. If this exon contains domains critical for dystrophin's normal subcellular localization—such as membrane-binding regions or cytoskeletal interaction sites—the protein will be produced but won't localize properly to the sarcolemma where it's needed. This explains why protein levels increase but clinical benefit remains modest. Looking at the incorrect options: Choice A is wrong because if antisense oligonucleotides interfered with translation, you wouldn't see increased dystrophin levels at all. Choice C incorrectly suggests that muscle regeneration dilutes the signal—this wouldn't explain altered localization patterns, just reduced intensity. Choice D proposes missing post-translational modifications, but the localization defect is more likely due to the primary sequence changes from exon deletion rather than secondary modifications. The key insight is that exon skipping creates a shortened but in-frame protein that may lack essential functional domains. While this can restore some function, it's not equivalent to wild-type protein. Study tip: For gene therapy questions, always consider how the intervention affects protein structure first, then think about how structural changes impact function and localization.

Question 15

A biotechnology company is developing a gene therapy for hemophilia B using an AAV vector to deliver the Factor IX gene. They discover that patients with pre-existing liver disease show reduced therapeutic efficacy compared to healthy individuals. Which characteristic of the diseased liver most likely accounts for this difference?

  1. Increased expression of restriction endonucleases that degrade the incoming AAV vector DNA
  2. Reduced hepatocyte proliferation rate, which decreases the opportunity for vector integration
  3. Impaired protein processing and secretion machinery affecting Factor IX production and release (correct answer)
  4. Enhanced immune surveillance in diseased liver tissue leading to rapid clearance of transduced cells
  5. Altered liver blood flow patterns that prevent efficient vector distribution to target hepatocytes
Explanation: When evaluating gene therapy efficacy, you need to consider the entire pathway from vector delivery to therapeutic protein function. AAV-mediated gene therapy for hemophilia B relies not just on successful gene delivery, but on the target tissue's ability to produce and secrete functional Factor IX protein. The diseased liver's compromised protein processing and secretion machinery is the key limiting factor here. Liver disease typically involves hepatocyte damage that impairs the endoplasmic reticulum and Golgi apparatus - the cellular machinery responsible for protein folding, post-translational modifications, and secretion. Since Factor IX requires extensive processing including gamma-carboxylation and proper folding to be functional, damaged hepatocytes cannot effectively produce therapeutic levels of active protein even when the gene is successfully delivered. Option A is incorrect because mammalian cells don't typically express restriction endonucleases that would degrade AAV vectors. Option B misunderstands AAV biology - these vectors don't require cell division for transduction and typically remain episomal rather than integrating into the host genome. Option D, while immune responses can affect gene therapy, doesn't explain the specific difference between healthy and diseased liver tissue in terms of baseline therapeutic efficacy. For gene therapy questions, always trace the complete pathway from vector delivery to therapeutic outcome. The bottleneck isn't always at the gene delivery stage - often it's the target tissue's capacity to translate that genetic information into functional protein. Understanding tissue-specific pathophysiology helps predict where gene therapy might face limitations.

Question 16

Researchers are using prime editing to correct a 4-base pair deletion in the HEXA gene that causes Tay-Sachs disease. They design a prime editing guide RNA (pegRNA) but observe low editing efficiency. Analysis reveals that the reverse transcriptase extension product is being degraded before successful integration. Which modification would most likely improve editing efficiency?

  1. Extend the length of the primer binding site in the pegRNA design
  2. Include a protease inhibitor to prevent reverse transcriptase degradation during the reaction
  3. Design the pegRNA to incorporate modified nucleotides that resist cellular nucleases (correct answer)
  4. Use a nicking Cas9 variant instead of prime editor to create a more stable intermediate
  5. Co-transfect with additional reverse transcriptase enzyme to overwhelm the degradation machinery
Explanation: When you encounter prime editing questions, focus on the specific mechanism: prime editors use a reverse transcriptase to synthesize DNA from the pegRNA template, but this intermediate product is vulnerable to cellular degradation before integration occurs. The correct answer is C because the problem explicitly states that "the reverse transcriptase extension product is being degraded before successful integration." This degradation occurs due to cellular nucleases that recognize and cleave the newly synthesized DNA. By incorporating modified nucleotides that resist nuclease activity (such as phosphorothioate linkages or 2'-O-methyl modifications), you can protect the extension product long enough for successful integration into the genome. Let's examine why the other options won't solve this specific problem. Option A (extending the primer binding site) might improve initial binding but won't prevent degradation of the extension product once it's formed. Option B (protease inhibitors) targets protein degradation, but the issue here is nuclease activity against DNA, not protease activity against the reverse transcriptase enzyme itself. Option D (using nicking Cas9) fundamentally changes the editing mechanism away from prime editing, which defeats the purpose of using this specific technology for precise insertions. For prime editing questions, always identify where in the multi-step process the failure occurs: pegRNA binding, reverse transcription, protection from degradation, or final integration. The solution must directly address the specific bottleneck mentioned in the question stem.

Question 17

A research team is developing a CRISPR activation (CRISPRa) therapy for Parkinson's disease by upregulating endogenous GDNF expression in dopaminergic neurons. They use dCas9 fused to transcriptional activator domains and target multiple sites in the GDNF promoter. While the approach increases GDNF mRNA levels, the therapeutic benefit is limited. What factor most likely constrains the effectiveness of this strategy?

  1. GDNF protein requires post-translational processing that is impaired in Parkinson's disease neurons
  2. Increased GDNF expression triggers negative feedback loops that limit its neuroprotective activity
  3. The CRISPRa system causes off-target activation of genes that counteract GDNF's beneficial effects
  4. GDNF upregulation alone cannot reverse the advanced neurodegeneration already present in diseased neurons (correct answer)
  5. Dopaminergic neurons lack the cellular machinery required to secrete GDNF protein effectively
Explanation: When evaluating gene therapy approaches for neurodegenerative diseases, you need to consider both the therapeutic mechanism and the realistic limitations imposed by disease progression. CRISPR activation (CRISPRa) can effectively increase target gene expression, but its success depends on whether the underlying cellular machinery remains functional. The correct answer is D because Parkinson's disease involves progressive loss of dopaminergic neurons in the substantia nigra. While GDNF (glial cell-derived neurotrophic factor) has neuroprotective properties and can support neuronal survival, it cannot resurrect neurons that have already died or reverse severe structural damage to remaining neurons. By the time Parkinson's symptoms appear, patients have typically lost 50-80% of their dopaminergic neurons. CRISPRa therapy would increase GDNF in surviving neurons, but this cannot restore the lost neuronal population or fully repair the damaged circuitry. Option A is incorrect because GDNF processing mechanisms generally remain intact in Parkinson's neurons—the issue isn't protein maturation but rather the extent of neuronal loss. Option B misrepresents GDNF biology; while some growth factors have negative feedback mechanisms, GDNF's neuroprotective effects aren't significantly limited by such loops in this context. Option C, while off-target effects are always a concern with CRISPR systems, doesn't represent the primary limitation when the therapy successfully increases target gene expression as described. For neurodegenerative disease questions, remember that timing matters critically. Therapies work best when applied early in disease progression, before extensive irreversible damage occurs. Always consider whether the intervention addresses the root pathology or just supports remaining healthy tissue.

Question 18

Researchers are using CRISPR interference (CRISPRi) to downregulate PCSK9 expression as a potential therapy for hypercholesterolemia. They use a catalytically dead Cas9 (dCas9) fused to a transcriptional repressor domain. The treatment successfully reduces PCSK9 mRNA levels, but patients show variable responses in cholesterol reduction. What factor most likely contributes to this variability?

  1. Individual differences in guide RNA stability affect the duration of PCSK9 repression
  2. Genetic variants in the PCSK9 promoter region alter the accessibility of the CRISPRi target sites
  3. Existing PCSK9 protein levels vary between patients and have different half-lives in circulation (correct answer)
  4. Alternative splicing of PCSK9 creates isoforms that escape CRISPRi-mediated repression
  5. Compensatory upregulation of other cholesterol regulatory genes masks the PCSK9 reduction effects
Explanation: When evaluating gene therapy approaches like CRISPRi, you need to consider the entire pathway from gene expression to functional protein effects. CRISPRi works by blocking transcription, but the therapeutic outcome depends on how quickly existing proteins are cleared from the system. The correct answer is C because PCSK9 protein that was already present before treatment continues to function in cholesterol regulation. Since CRISPRi reduces new mRNA production, patients will only see cholesterol improvements as their existing PCSK9 protein degrades naturally. Individual differences in baseline PCSK9 protein levels and protein turnover rates create significant variability in treatment response timing and magnitude. Option A is incorrect because guide RNA stability affects treatment duration, not the variability in initial response between patients. Even with stable guide RNAs, patients would still show different cholesterol responses based on their existing protein levels. Option B misunderstands the scenario - if promoter variants affected CRISPRi binding, you'd see differences in mRNA reduction, but the question states mRNA levels are successfully reduced in all patients. Option D incorrectly suggests alternative splicing as the primary variable, but splice variants would likely show up as incomplete mRNA reduction rather than uniform mRNA reduction with variable protein effects. Remember that gene therapies targeting transcription have a delayed effect because they must wait for existing protein turnover. Always consider the time lag between successful gene silencing and functional protein depletion when evaluating therapeutic variability.

Question 19

Scientists are using in vivo CRISPR gene editing to treat hereditary transthyretin amyloidosis by knocking out the TTR gene in hepatocytes. They deliver the CRISPR components via lipid nanoparticles but observe that editing efficiency varies significantly between different liver lobes. Analysis reveals that the nanoparticles preferentially accumulate in periportal hepatocytes rather than pericentral hepatocytes. What property of the liver microvasculature most likely contributes to this distribution pattern?

  1. Periportal regions have higher blood flow rates that enhance nanoparticle delivery efficiency
  2. Fenestrations in liver sinusoidal endothelium are larger in periportal compared to pericentral regions (correct answer)
  3. Kupffer cell density is lower in periportal areas, reducing nanoparticle clearance by phagocytosis
  4. Pericentral hepatocytes express higher levels of efflux pumps that exclude lipid nanoparticles
  5. The basement membrane surrounding periportal sinusoids has enhanced permeability to lipid-based carriers
Explanation: When you encounter questions about drug delivery to specific liver regions, focus on the unique microanatomy of hepatic sinusoids and how it affects particle distribution. The liver's sinusoidal endothelium contains fenestrations (pores) that allow materials to pass from blood into the space of Disse and reach hepatocytes. Critically, these fenestrations vary in size across the liver lobule. Periportal regions (near the portal triad) have larger fenestrations compared to pericentral regions (near the central vein). This size gradient means lipid nanoparticles can more easily extravasate through the larger pores in periportal areas, leading to preferential accumulation in periportal hepatocytes rather than pericentral ones. Option A is incorrect because while periportal regions do receive fresh oxygenated blood first, blood flow rate differences don't explain the selective accumulation pattern observed. Option C misrepresents Kupffer cell distribution - these macrophages are actually more abundant in periportal regions, not less, yet nanoparticles still accumulate there preferentially. Option D incorrectly suggests efflux pumps in pericentral hepatocytes actively exclude nanoparticles, but the distribution pattern is better explained by differential entry rather than active exclusion. The correct answer is B - the larger fenestrations in periportal sinusoidal endothelium facilitate greater nanoparticle extravasation in these regions. Remember: Liver zonation affects not just metabolic function but also drug delivery. The fenestration size gradient is a key factor determining how therapeutic particles distribute within liver lobules.

Question 20

Scientists are developing a CRISPR-based therapy for sickle cell disease by editing the patient's hematopoietic stem cells to reactivate fetal hemoglobin (HbF) production. They target the BCL11A gene, which normally represses HbF expression in adult cells. After successful editing and transplantation, some patients show increased HbF levels but still experience sickling episodes. What is the most likely explanation for the incomplete therapeutic response?

  1. The edited stem cells failed to engraft properly in the patient's bone marrow microenvironment
  2. BCL11A editing was successful, but other transcriptional repressors continue to limit HbF expression
  3. The patients developed immune responses against the fetal hemoglobin protein as a foreign antigen
  4. Off-target CRISPR effects disrupted other genes required for normal hemoglobin chain assembly
  5. The increased HbF levels were insufficient to prevent sickling under physiological stress conditions (correct answer)
Explanation: When analyzing CRISPR gene therapy outcomes, you need to consider that therapeutic success depends on both the molecular editing efficiency and the biological context of the target pathway. In this sickle cell therapy, scientists successfully edited BCL11A to reactivate fetal hemoglobin (HbF) production, and patients did show increased HbF levels. However, the continued sickling episodes despite higher HbF suggests that while the editing worked, other regulatory mechanisms are still limiting HbF to subtherapeutic levels. Fetal hemoglobin expression is controlled by multiple transcriptional repressors working in concert—BCL11A is a major one, but others like KLF1 and ZBTB7A also suppress gamma-globin genes. Even with BCL11A knocked out, these remaining repressors can maintain significant suppression of HbF production. Option A is incorrect because the increased HbF levels demonstrate that the edited cells did engraft and function. Option C misunderstands immunology—HbF isn't foreign since humans naturally produce it during fetal development, and the immune system wouldn't target it as an antigen. Option D suggests off-target effects disrupting hemoglobin assembly, but this would likely cause different symptoms than continued sickling with increased HbF. For gene therapy questions, remember that biological pathways often have redundant regulatory mechanisms. Single-gene edits may provide partial therapeutic benefit but rarely achieve complete correction when multiple factors control the target pathway. This is why combination approaches targeting multiple repressors are being developed for more complete HbF reactivation.